NASDAQ:SGEN Seagen (SGEN) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free SGEN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$228.74▼$228.7450-Day Range$228.74▼$228.7452-Week Range$123.77▼$228.96Volume86 shsAverage Volume1.48 million shsMarket Capitalization$42.93 billionP/E RatioN/ADividend YieldN/APrice Target$229.00 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability Get Seagen alerts: Email Address Seagen MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside0.1% Upside$229.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.63Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.82) to ($1.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.24 out of 5 starsMedical Sector916th out of 938 stocksBiotechnology Industry44th out of 47 stocks 1.0 Analyst's Opinion Consensus RatingSeagen has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $229.00, Seagen has a forecasted upside of 0.1% from its current price of $228.74.Amount of Analyst CoverageSeagen has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for SGEN. Previous Next 0.0 Dividend Strength Dividend YieldSeagen does not currently pay a dividend.Dividend GrowthSeagen does not have a long track record of dividend growth. Previous Next 2.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSeagen has received a 15.14% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Brentuximab vedotin", "Enfortumab vedotin", and "Tucatinib" products. See details.Environmental SustainabilityThe Environmental Impact score for Seagen is -2.63. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for SGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Seagen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seagen insiders have not sold or bought any company stock.Percentage Held by Insiders25.90% of the stock of Seagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.26% of the stock of Seagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Seagen are expected to grow in the coming year, from ($3.82) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seagen is -57.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seagen is -57.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeagen has a P/B Ratio of 15.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Seagen Stock (NASDAQ:SGEN)Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.Read More Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> SGEN Stock News HeadlinesMarch 20, 2024 | msn.comRon Baron Portfolio Magic: Building Your Financial FutureMarch 13, 2024 | msn.comBailouts are back, Fed outlook reassessed, Pfizer M&A - what's moving marketsMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 1, 2024 | bizjournals.comPfizer shutting down Seagen's $350M construction project in EverettFebruary 24, 2024 | finance.yahoo.comNeuralink’s First Brain Implant Patient Can Control Mouse with Thoughts, Musk SaysFebruary 23, 2024 | finance.yahoo.comMRNA Feb 2024 64.000 putFebruary 23, 2024 | finance.yahoo.comMRNA Feb 2024 77.000 callFebruary 23, 2024 | msn.comPfizer adds bull at Guggenheim on ex-COVID prospectsMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.February 22, 2024 | finance.yahoo.comMRNA Feb 2024 67.000 putFebruary 12, 2024 | msn.comPfizer touts cancer efforts in first Super Bowl commercialFebruary 10, 2024 | finance.yahoo.comPRIMECAP Management's Strategic Exits and New Positions Highlight Q4 MovesJanuary 29, 2024 | msn.comPfizer Q4 results on deck amid gloomy earnings outlookJanuary 28, 2024 | za.investing.comPro Research: Wall Street eyes Seagen's growth trajectoryDecember 30, 2023 | ca.finance.yahoo.comSGEN Jan 2024 210.000 putDecember 30, 2023 | ca.finance.yahoo.comSGEN Jan 2024 235.000 put(CONTRDecember 30, 2023 | uk.finance.yahoo.comSGEN Dec 2023 195.000 put(CONTRDecember 27, 2023 | za.investing.comPro Research: Wall Street dives into Seagen's oncology advancesDecember 22, 2023 | seekingalpha.comHBM Gets Health Boost From Drug Licensing DealsDecember 14, 2023 | msn.comPfizer Shares Slump After Waning Covid Sales Hurt 2024 OutlookDecember 13, 2023 | seekingalpha.comTake-Two Interactive Software to replace Seagen on Nasdaq-100 IndexDecember 13, 2023 | msn.comPfizer to Establish New Oncology Division Following Completion of Seagen DealDecember 13, 2023 | msn.comPfizer slips as 2024 guidance with Seagen buyout disappointsDecember 12, 2023 | nasdaq.comPfizer gets OK for $43-bln Seagen deal after donating cancer drug rightsDecember 11, 2023 | benzinga.comWhat the Options Market Tells Us About SeagenDecember 11, 2023 | businesswire.com88% of patients with advanced stage classical Hodgkin Lymphoma in trial remained progression free at 24 months –December 10, 2023 | finance.yahoo.comADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin LymphomaSee More Headlines Receive SGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SGEN CUSIP81257810 CIK1060736 Webwww.seattlegenetics.com Phone(425) 527-4000Fax425-527-4001Employees3,256Year Founded1998Price Target and Rating Average Stock Price Target$229.00 High Stock Price Target$229.00 Low Stock Price Target$229.00 Potential Upside/Downside+0.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($4.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-610,310,000.00 Net Margins-32.61% Pretax Margin-32.12% Return on Equity-28.06% Return on Assets-20.92% Debt Debt-to-Equity RatioN/A Current Ratio2.67 Quick Ratio2.12 Sales & Book Value Annual Sales$2.30 billion Price / Sales18.66 Cash FlowN/A Price / Cash FlowN/A Book Value$15.10 per share Price / Book15.15Miscellaneous Outstanding Shares187,698,000Free Float139,084,000Market Cap$42.93 billion OptionableOptionable Beta0.32 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. David R. Epstein B.Sc. (Age 61)M.B.A., CEO & Director Comp: $1.39MMr. Todd E. Simpson (Age 62)Chief Financial Officer Comp: $1.26MDr. Vaughn B. Himes Ph.D. (Age 62)Chief Technical Officer Comp: $1.08MMs. Jean I. Liu J.D. (Age 55)M.S., Chief Legal Officer & Corporate Secretary Comp: $1.23MMr. Charles R. Romp (Age 55)Executive Vice President of Commercial U.S. Comp: $1.08MDr. Roger D. Dansey M.D. (Age 67)Chief Medical Officer and President of Research & Development Comp: $2.48MMr. William ComptonSenior VP of Global Information Technology & CIOMr. David CaouetteVice President of Corporate CommunicationsMr. Matt SkeltonVice President of MarketingMs. Peggy M. PinkstonChief Human Resources OfficerMore ExecutivesKey CompetitorsHumanaNYSE:HUMIDEXX LaboratoriesNASDAQ:IDXXCenteneNYSE:CNCModernaNASDAQ:MRNAIQVIANYSE:IQVView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Sold 1,155,100 shares on 3/27/2024Ownership: 0.000%Goldman Sachs Group Inc.Sold 188,800 shares on 3/1/2024Ownership: 0.000%Bluefin Capital Management LLCSold 5,472,500 shares on 2/16/2024Ownership: 0.000%Wolverine Trading LLCSold 3,500 shares on 2/15/2024Ownership: 0.000%Prelude Capital Management LLCSold 6,100 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions Should I Buy Seagen Stock? SGEN Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Seagen Inc.: Seagen Inc. has a strong product portfolio including ADCETRIS, PADCEV, and TUKYSA, which are innovative therapies for cancer treatment. Recent acquisition of Seagen Inc. shares by Hudson Bay Capital Management LP indicates investor confidence in the company's potential growth. Seagen Inc. has collaboration agreements with reputable companies like Takeda Pharmaceutical, Merck, and Genmab, enhancing its research and development capabilities. Seagen Inc. is continuously developing new therapies like TIVDAK, Ladiratuzumab Vedotin, and Disitamab Vedotin, expanding its product pipeline. Despite being a subsidiary of Pfizer Inc., Seagen Inc. operates independently, allowing it to focus on its core competencies in biotechnology. Cons Investors should be bearish about investing in Seagen Inc. for these reasons: Market volatility in the biotechnology sector can impact Seagen Inc.'s stock price, leading to potential investment risks. Regulatory challenges and approval processes for new drugs can cause delays in product launches, affecting revenue generation. Competition in the biotechnology industry is intense, with other companies also developing innovative cancer therapies, posing a threat to Seagen Inc.'s market share. Fluctuations in healthcare policies and reimbursement rates can influence the adoption of Seagen Inc.'s products, affecting financial performance. Investing in biotechnology companies like Seagen Inc. requires a high tolerance for risk due to the inherent uncertainties in drug development and commercialization. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, March 25, 2024. Please send any questions or comments about these Seagen pros and cons to contact@marketbeat.com. SGEN Stock Analysis - Frequently Asked Questions Should I buy or sell Seagen stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares. View SGEN analyst ratings or view top-rated stocks. What is Seagen's stock price target for 2024? 2 brokerages have issued 1-year price objectives for Seagen's stock. Their SGEN share price targets range from $229.00 to $229.00. On average, they expect the company's stock price to reach $229.00 in the next year. This suggests a possible upside of 0.1% from the stock's current price. View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts. How were Seagen's earnings last quarter? Seagen Inc. (NASDAQ:SGEN) posted its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by $0.33. The biotechnology company earned $648.65 million during the quarter, compared to analyst estimates of $635.10 million. Seagen had a negative net margin of 32.61% and a negative trailing twelve-month return on equity of 28.06%. The firm's revenue for the quarter was up 27.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.03) earnings per share. What ETFs hold Seagen's stock? ETFs with the largest weight of Seagen (NASDAQ:SGEN) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), AltShares Event-Driven ET (EVNT), Principal Healthcare Innovators ETF (BTEC) and AltShares Merger Arbitrage ETF (ARB). What is Clay B. Siegall's approval rating as Seagen's CEO? 107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Seagen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA). Who are Seagen's major shareholders? Seagen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Clear Street Markets LLC (0.00%), Public Sector Pension Investment Board (0.00%), Mint Tower Capital Management B.V. (0.00%), Neuberger Berman Group LLC (0.00%), Cowen AND Company LLC (0.00%) and Segantii Capital Management Ltd (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David R Epstein, David W Gryska, Jean I Liu, Jean I Liu, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes. View institutional ownership trends. Does Seagen have any subsidiaries? The following companies are subsidiares of Seagen: Cascadian Therapeutics.Read More This page (NASDAQ:SGEN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.